alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Sturge-Weber Syndrome

## What is Sturge-Weber syndrome? 

Sturge-Weber syndrome is a rare, neurological disorder present at birth and characterized by a port-wine stain birthmark on the forehead and upper eyelid on one side of the face. The birthmark can vary in color from light pink to deep purple and is caused by an overabundance of capillaries (small blood vessels) around the trigeminal nerve just beneath the surface of the face.  

Sturge-Weber syndrome is also accompanied by abnormal blood vessels on the brain's surface and the loss of tissue (atrophy) with deposits of calcium (calcification) in the cerebral cortex of the brain on the same side as the birthmark. Sturge-Weber syndrome rarely affects other body organs.

Neurological symptoms may include:
              - Seizures that begin in infancy and may worsen with age. Convulsions usually happen on the side of the body opposite the birthmark and vary in severity
              - Intermittent or permanent muscle weakness  
              - Developmental delays and cognitive impairment
              - Glaucoma (increased pressure within the eye) at birth or later. The increased pressure within the eye can cause the eyeball to enlarge and bulge out of its socket (buphthalmos)
              - Migraines

Treatment is symptomatic. Laser treatment may be used to lighten or remove the birthmark. Anticonvulsant medications may be used to control seizures. Physical therapy may help with muscle weakness and educational therapy may help those with impaired cognition or developmental delays.  Doctors recommend yearly monitoring for glaucoma.

Although it is possible for the birthmark and atrophy in the cerebral cortex to be present without symptoms, most infants will develop convulsive seizures during their first year of life. There is a greater likelihood of intellectual impairment when seizures start before the age of 2 and are resistant to treatment.

file-medical

## How can I or my loved one help improve care for people with Sturge-Weber syndrome?

Consider participating in a clinical trial so clinicians and scientists can learn more about Sturge-Weber syndrome and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease. 

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them. 

For information about participating in clinical research visit NIH Clinical Research Trials and You. Learn about clinical trials currently looking for people with Sturge-Weber syndrome at Clinicaltrials.gov.
> Where can I find more information about Sturge-Weber syndrome?
Information may be available from the following organizations and resources:

March of DimesPhone: 888-663-4637 

MedlinePlus

National Eye Institute (NEI)

The Sturge-Weber FoundationPhone: 973-895-4445

Vascular Birthmarks FoundationPhone: 877- 823-4646

book-open
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

EL PASO COUNTY HOSPITAL 

DISTRICT D/B/A UNIVERSITY 

MEDICAL CENTER OF EL PASO 

AND UMC OF EL PASO,

APPELLANTS,

V.

NOEMI E. CHAVEZ,

APPELLEE.

§

§

§

§

§

§

No. 08-15-00153-CV

Appeal from the

327th District Court

of El Paso County, Texas

(TC# 2012DCV06654)

J U D G M E N T

The Court has considered this cause on the Appellants’ motion to dismiss the appeal and 

concludes the appeal should be dismissed, in accordance with the opinion of this Court. We 

therefore dismiss the appeal. This decision shall be certified below for observance.

IT IS SO ORDERED THIS 10TH DAY OF JULY, 2015.

YVONNE T. RODRIGUEZ, Justice

Before McClure, C.J., Rodriguez and Hughes, JJ.
IV 

116TH CONGRESS 

1ST SESSION H. RES. 477 

Requiring that the House authorize any judicial proceeding on behalf of 

any committee. 

IN THE HOUSE OF REPRESENTATIVES 

JULY 9, 2019 

Mr. BRADY submitted the following resolution; which was referred to the 

Committee on Rules 

RESOLUTION 

Requiring that the House authorize any judicial proceeding 

on behalf of any committee. 

1 Resolved, That the second resolving clause in House 

2 Resolution 430 (116th Congress) is amended by striking 

3 ‘‘Bipartisan Legal Advisory Group’’ the first place it ap4 pears and inserting ‘‘House of Representatives’’ and by 

5 striking the second sentence. 

Æ 


pbinns on DSK79D2C42PROD with BILLS
#### In the Matter of Barbara N., Appellant. Robert Doar, Respondent.

Submitted July 8, 2013;

decided September 12, 2013

Motion for leave to appeal dismissed as untimely *(see*CPLR 5513 [b]; 5514 [c]).
* Pursuant to 5 TH C IR

. R. 47.5, the Court has determined that this opinion should not be

published and is not precedent except under the limited circumstances set forth in 5 TH C IR

. R. 47.5.4.

1 336 U.S. 738 (1967).

UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 97-10162 Summary Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus

MICHAEL RAPAPPORT, Defendant-Appellant.

Appeal from the United States District Court

for the Northern District of Texas (3:96-CR-102-4-D)

August 17, 1998

Before POLITZ, Chief Judge, HIGGINBOTHAM and SMITH, Circuit Judges.

PER CURIAM: *

Court-appointed counsel for Michael Rapapport has filed a brief as required

by Anders v. California

, 1 and moved to withdraw. Rapapport sought leave to

proceed pro se

. Counsel’s motion was granted, excusing him from further

responsibilities herein, and Rapapport was given 30 days in which to file a brief,

should he opt to do so, raising any matter he deemed relevant to his appeal. The2

time allowed has expired and no such filing has been made.

Our independent review of counsel’s brief and the record discloses no

nonfrivolous issue which ma y be presented herein. Accordingly, the appeal is

DISMISSED.
Exhibit 99.1
------------




                       CERTIFICATION PURSUANT TO
                        18 U.S.C. SECTION 1350,
                        AS ADOPTED PURSUANT TO
             SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Landauer, Inc. (the "Company")
on Form 10-Q for the period ending December 31, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Brent A. Latta, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section  1350, as adopted pursuant to Section  906 of the
Sarbanes-Oxley Act of 2002, that:

     (1)   The Report fully complies with the requirements of
           section 13(a) or 15(d) of the Securities Exchange Act
           of 1934; and

     (2)   The information contained in the Report fairly presents,
           in all material respects, the financial condition and
           result of operations of the Company.




                                  /s/ Brent A. Latta
                                  -----------------------
                                  Brent A. Latta
                                  Chief Executive Officer


February 12, 2003
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                            2043
<SECURITIES>                                     19585
<RECEIVABLES>                                     6490
<ALLOWANCES>                                       465
<INVENTORY>                                       5920
<CURRENT-ASSETS>                                 37454
<PP&E>                                            7686
<DEPRECIATION>                                    5539
<TOTAL-ASSETS>                                   62733
<CURRENT-LIABILITIES>                             8931
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         30913
<OTHER-SE>                                       22889
<TOTAL-LIABILITY-AND-EQUITY>                     62733
<SALES>                                          52078
<TOTAL-REVENUES>                                 52078
<CGS>                                            21457
<TOTAL-COSTS>                                    47727
<OTHER-EXPENSES>                                (2495)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                   6846
<INCOME-TAX>                                      2149
<INCOME-CONTINUING>                               4697
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      4697
<EPS-PRIMARY>                                     0.50
<EPS-DILUTED>                                     0.50
        

</TABLE>
Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER 
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Brekford International Corp. (the Company) on Form 10-Q for the quarter ended September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Tin M. Khin, Principal Financial Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.



| |  |                                                                
| |  | ---------------------------------------------------------------
| |  | /s/ Tin M. Khin                                                
| |  | Tin M. Khin
Principal Financial Officer

Date: November 2, 2009



The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Section 1350 of Chapter 63 of Title 18 of the United States Code) and is not being filed as part of the Report or as a separate disclosure document.
** **

**Exhibit 23**

**Spherix Incorporated**

 

----

 

**CONSENT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM**

 

We have issued ourreports dated April 3, 2008, accompanying the consolidated financialstatements included in the Annual Report of Spherix Incorporated on Form 10-Kfor the year ended December 31, 2007.  We hereby consent to theincorporation by reference of said reports in the Registration Statements ofSpherix Incorporated on Form S-8 (File No. 333-66053 effective October 23,1998), on Forms S-3 (File No. 333-44973 effective March 23, 1998,333-79593 effective May 28, 1999, 333-32504 effective April 19, 2000,and 333-116422 effective June 14, 2004) and on Forms S-2 (File No. 333-126930effective October 4, 2005).

 

/s/  Grant Thornton LLP

 

Baltimore, Maryland

April 3, 2008

 

----
# Job Vacancy Announcement - Budget Analyst 

**Department of Health and Human Services (HHS)National Institutes of Health (NIH)National Institute of Mental Health (NIMH)Office of Management (OM)Budget & Analytics Branch (BAB)**

## Program Overview

The NIMH Office of Management (OM) provides strategic leadership, direction, oversight and consultation on the business and management operations in support of the Institute’s scientific mission. This position is located within the Budget & Analytics Branch (BAB) in the OM.

## Position Duties

The incumbent must have the ability to work independently and possess strong communication skills. The selectee will be responsible for assisting staff with all phases of the budget process to include formulation, presentation and execution. Applicants must be able to assemble and analyze accurate data for presentation to senior management; organize results of analyses into coherent written or graphical reports and presentations; allocate, monitor and evaluate expenditure of account funds; and develop and implement methods, procedures, and systems to enhance and refine the monitoring and management of Division and Institute-supported programs and data. The ability to demonstrate a high-level of competency with existing enterprise and institute-level databases and data analysis systems and applications to research, gather, and analyze complex data and make recommendations based on analysis is preferred.

## Qualifications

Minimum of three (3) years related management experience. Proficiency with IT software applications (e.g., Microsoft Excel). Skill in querying data and applying both analytical and evaluative methods and Technique is a must. Strong organizational skills and the ability to prioritize complex tasks.

## How to Apply

Interested candidates should send a letter of interest and resume to: NIMHSearch@nih.gov.

## Benefits

The Budget Analyst will be selected at a salary commensurate with their qualifications and experience. In addition, full benefits, including leave, health and life insurance may be provided.

### HHS and NIH are equal opportunity employers.

The NIH is dedicated to building a diverse community in its training and employment programs and encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                             739
<SECURITIES>                                         0
<RECEIVABLES>                                      569
<ALLOWANCES>                                         0
<INVENTORY>                                      1,382
<CURRENT-ASSETS>                                 3,419
<PP&E>                                          13,433
<DEPRECIATION>                                   8,116
<TOTAL-ASSETS>                                  11,209
<CURRENT-LIABILITIES>                            2,136
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           420
<OTHER-SE>                                       7,247
<TOTAL-LIABILITY-AND-EQUITY>                    11,209
<SALES>                                         23,214
<TOTAL-REVENUES>                                25,160
<CGS>                                           11,717
<TOTAL-COSTS>                                   23,380
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 177
<INCOME-PRETAX>                                  1,705
<INCOME-TAX>                                       341
<INCOME-CONTINUING>                              1,364
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     1,364
<EPS-BASIC>                                        .73
<EPS-DILUTED>                                      .71


</TABLE>
# Hemifacial Spasm

## What is hemifacial spasm? 

Hemifacial spasm is a neuromuscular disorder that involves frequent contractions or spasms of the muscles on one side of the face. The spasms are involuntary, meaning they happen on their own without trying. The disorder occurs in both men and women, yet it is more common in middle-aged or older women. It is also much more common in the Asian population. 

The first symptom is usually twitching of the eyelid muscle that comes and goes. This can then lead to forced closure of the eye. The spasm may then gradually spread to involve the muscles of the lower face, pulling the mouth to one side. Eventually the spasms involve all of the muscles on one side of the face almost nonstop. Rarely, doctors see individuals with spasm on both sides of the face.

The condition may be caused by:
              - A facial nerve injury
              - A tumor
              - No apparent cause

Most often hemifacial spasm is caused by a blood vessel pressing on the facial nerve at the place where it exits the brainstem.

Injection of botulinum toxin into the affected areas is the most effective therapy. It is also the only one used in most cases. Microvascular decompression surgery relieves pressure on the facial nerve and can provide relief in many cases. This surgery can have significant side-effects, so risks and benefits have to be weighed. Drug therapy generally does not work.

The outlook for people with hemifacial spasm depends on the treatment and how they respond. Some people will be nearly free of symptoms with injection therapy. Some may require surgery. In most cases, people are able to find balance between symptoms they can tolerate and risks of treatment.

file-medical

## How can I or my loved one help improve care for people with hemifacial spasm?

Consider participating in a clinical trial so clinicians and scientists can learn more about hemifacial spasm and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease. 

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them. 

For information about participating in clinical research visit NIH Clinical Research Trials and You. Learn about clinical trials currently looking for people with hemifacial spasm at Clinicaltrials.gov.
> Where can I find more information about hemifacial spasm?                      
The following organizations and resources can help individuals, families, friends, and caregivers of people living with hemifacial spasm:

Benign Essential Blepharospasm Research FoundationPhone: 409-832-0788

National Organization for Rare Disorders (NORD)Phone: 203-744-0100 or 800-999-6673; 844-259-7178 Spanish

book-open
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 12-1011

UNITED STATES ex rel. BENJAMIN CARTER,

Plaintiff - Appellant,

v.

HALLIBURTON CO; KELLOGG BROWN & ROOT SERVICES, INC.; SERVICE 

EMPLOYEES INTERNATIONAL, INC.; KBR, INC.,

Defendants - Appellees.

On Remand from the Supreme Court of the United States.

(S. Ct. No. 12-1497)

Submitted: June 29, 2015 Decided: July 14, 2015

Before AGEE, WYNN, and FLOYD, Circuit Judges.

Affirmed by unpublished per curiam order.

ARGUED: William Clifton Holmes, DUNLAP, GRUBB & WEAVER, PC, 

Leesburg, Virginia, for Appellant. John Martin Faust, LAW 

OFFICE OF JOHN M. FAUST, PLLC, Washington, D.C., for Appellees. 

ON BRIEF: Thomas M. Dunlap, David Ludwig, DUNLAP, GRUBB & 

WEAVER, PC, Leesburg, Virginia, for Appellant. Craig D. 

Margolis, Tirzah S. Lollar, Kathryn B. Codd, VINSON & ELKINS 

LLP, Washington, D.C., for Appellees. 
2

ORDER

PER CURIAM:

This case returns to us on remand after the Supreme Court 

granted Kellogg Brown & Root Services, Inc.’s petition for 

certiorari, and reversed in part and affirmed in part our 

decision in United States ex rel. Carter v. Halliburton Co., 710 

F.3d 171 (4th Cir. 2013). The only issue left for resolution is 

whether Carter timely filed his complaint under the principle of 

equitable tolling. Appellees–Defendants have filed a motion for 

summary affirmance under Fourth Circuit Local Rule 27(f). 

Because Carter raised the issue of equitable tolling for the 

first time in a motion to file a surreply and has not appealed 

the district court’s denial of that motion, we find that the 

issue is not properly before us and that equitable tolling is 

thus unavailable. See ACLU v. Holder, 673 F.3d 245, 252 n.5 

(4th Cir. 2011). Therefore, we grant Appellees–Defendants’ 

motion for summary affirmance and affirm the district court’s 

judgment.

AFFIRMED
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-END>                               SEP-30-1999
<CASH>                                          104981
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                104981
<PP&E>                                           31032
<DEPRECIATION>                                   23700
<TOTAL-ASSETS>                                  112313
<CURRENT-LIABILITIES>                             6500
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                          2485
<OTHER-SE>                                      103328
<TOTAL-LIABILITY-AND-EQUITY>                    112313
<SALES>                                              0
<TOTAL-REVENUES>                                  1059
<CGS>                                                0
<TOTAL-COSTS>                                     8033
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 (6974)
<INCOME-TAX>                                       501
<INCOME-CONTINUING>                             (7475)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    (7475)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0


</TABLE>
Exhibit 32.3





CERTIFICATION PURSUANT TO SECTION 906


OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)





In connection with the Quarterly Report of BreitBurn Energy Partners L.P (the “Partnership”) on Form 10-Q for the period ended June 30, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James G. Jackson, Chief Financial Officer of BreitBurn GP, LLC, the general partner
of the Partnership, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:





(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.





/s/ JAMES G. JACKSONJames G. JacksonChief Financial Officer of BreitBurn GP, LLCDated:  August 10, 2009